[
  {
    "ts": null,
    "headline": "S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash",
    "summary": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
    "url": "https://finnhub.io/api/news?id=2c962a5d6369911f20d54803752bd0307ef39e280a10344546d37968e73cb860",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744304303,
      "headline": "S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash",
      "id": 133873314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
      "url": "https://finnhub.io/api/news?id=2c962a5d6369911f20d54803752bd0307ef39e280a10344546d37968e73cb860"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue Stock Could Be a Cure for Investors’ Headaches",
    "summary": "Kenvue Stock Could Be a Cure for Investors’ Headaches",
    "url": "https://finnhub.io/api/news?id=a94b71526899c4dd476d19e417ffe53749dacf70a2cd9a180caaa8d73ef85c2a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744296480,
      "headline": "Kenvue Stock Could Be a Cure for Investors’ Headaches",
      "id": 134146900,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Kenvue Stock Could Be a Cure for Investors’ Headaches",
      "url": "https://finnhub.io/api/news?id=a94b71526899c4dd476d19e417ffe53749dacf70a2cd9a180caaa8d73ef85c2a"
    }
  },
  {
    "ts": null,
    "headline": "Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finnhub.io/api/news?id=f627cbee576c2a8efabe6032840ae218de9736ddc01230af6f330c8d30008c7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744290912,
      "headline": "Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
      "id": 133853260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
      "url": "https://finnhub.io/api/news?id=f627cbee576c2a8efabe6032840ae218de9736ddc01230af6f330c8d30008c7d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=5b7c071e96a7f3b44c7d382c9180555e87314bb691abfd05f621ee394e51ad9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744290015,
      "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 133853263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=5b7c071e96a7f3b44c7d382c9180555e87314bb691abfd05f621ee394e51ad9c"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer’s Take On Johnson & Johnson (JNJ): Are Litigation Fears Creating a Rare Buying Opportunity?",
    "summary": "We recently published a list of Jim Cramer Says Tariff Pain Isn’t Over Yet And Reviews These 9 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer dissected […]",
    "url": "https://finnhub.io/api/news?id=14df08357362eb3aaabf09baf8b94c6aa51774f682449a3246c4dcf87a2c0d83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744288963,
      "headline": "Jim Cramer’s Take On Johnson & Johnson (JNJ): Are Litigation Fears Creating a Rare Buying Opportunity?",
      "id": 133844138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Says Tariff Pain Isn’t Over Yet And Reviews These 9 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer dissected […]",
      "url": "https://finnhub.io/api/news?id=14df08357362eb3aaabf09baf8b94c6aa51774f682449a3246c4dcf87a2c0d83"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis (PsO) to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously. These data, presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting, show adolescents treated with once daily icotrokinra achieved higher rates of clear or almost clear",
    "url": "https://finnhub.io/api/news?id=254f0de70a518ef6c28bf8164b8aa7891ef85067e2690693c880740a95350af5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744286700,
      "headline": "Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill",
      "id": 133844140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis (PsO) to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously. These data, presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting, show adolescents treated with once daily icotrokinra achieved higher rates of clear or almost clear",
      "url": "https://finnhub.io/api/news?id=254f0de70a518ef6c28bf8164b8aa7891ef85067e2690693c880740a95350af5"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income",
    "summary": "Stock market sell-offs like the one we're currently experiencing are challenging periods for investors.  For me, sell-offs are an opportunity to buy high-quality dividend stocks at lower prices, which enables me to lock in higher dividend yields.  Here's why I think they're great dividend stocks to buy for durable passive income.",
    "url": "https://finnhub.io/api/news?id=3f6755e6458adfb8e18d693b8563dff9c61501a760337fd1af9ae70f36236ba1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744276620,
      "headline": "Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income",
      "id": 133844141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stock market sell-offs like the one we're currently experiencing are challenging periods for investors.  For me, sell-offs are an opportunity to buy high-quality dividend stocks at lower prices, which enables me to lock in higher dividend yields.  Here's why I think they're great dividend stocks to buy for durable passive income.",
      "url": "https://finnhub.io/api/news?id=3f6755e6458adfb8e18d693b8563dff9c61501a760337fd1af9ae70f36236ba1"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now",
    "summary": "Three of the Dow's 30 components make for sensational buys amid a historic sell-off.",
    "url": "https://finnhub.io/api/news?id=caa6e3dd0ea82ed9b394bbe11207ee6c5cd1e794631180e5774741e48174d8db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744271460,
      "headline": "The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now",
      "id": 133844027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Three of the Dow's 30 components make for sensational buys amid a historic sell-off.",
      "url": "https://finnhub.io/api/news?id=caa6e3dd0ea82ed9b394bbe11207ee6c5cd1e794631180e5774741e48174d8db"
    }
  }
]